Established in December 2005, Jiangsu WNC Pharmaceutical Co., Ltd., with a registered capital of 38.461539 million yuan, is located in Yangkou Chemical Park, Rudong County, Jiangsu Province, covering an area of about 105 mu. It is a private scientific and technological enterprise integrating research, development, production and sales of pharmaceutical intermediates. The company has been successively rated as a high-tech enterprise in Jiangsu Province, a contract abiding and trustworthy enterprise in Jiangsu Province, and has established provincial engineering technology research center, Nantong enterprise technology center and other scientific research platforms.
The company's products include aliclam intermediate series, atorvastatin series, ezetimibe series, rosuvastatin series, indole series, etc. The company has a perfect ISO9001 quality management system.
Ezetimibe series products, (S) - (+) - 4-phenyl-2-oxazolidinone, passed the on-site quality audit of Merck, India TEVA and other companies.
Alikren intermediate series products, (S) - 4-Benzyl-2-oxazolidinone, have passed the on-site quality audit of Novartis, and are the largest production base of Novartis in Asia.
Atorvastatin series products have passed the on-site audit of product quality of international famous enterprises such as Dr. Reddys and SUN in India, and become high-quality suppliers of many international famous multinational companies.
The company attaches great importance to independent intellectual property rights. At present, it has more than 30 intellectual property rights patents and has registered 6 trademarks, among which the "Worcester" trademark was rated as "2013 Nantong Famous Trademark". Six of the company's products were rated as high-tech products in Jiangsu Province, and three were rated as Nantong Brand Products.
The company is a second-class safety standardization enterprise in Nantong City, which attaches great importance to the investment and management of environmental protection, safety and health, adheres to social benefits, pays attention to social responsibilities and obligations, adheres to safety first, adheres to people-oriented, and attaches equal importance to social and economic benefits; Continuously improve employee benefits, welfare and production and living environment.
The company attaches great importance to product research and development and technological innovation. It has built a research and development center with an area of about 1000 square meters, with an annual R&D investment of about 10 million yuan. It has successively established Jiangsu Provincial Engineering Technology Research Center, cooperated with Suzhou University to establish a provincial graduate workstation, and established industry university research cooperation with Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, East China University of Technology, Suzhou University, Lanzhou University and many other well-known universities. In the next few years, the company will continue to increase investment in product technology research and development, continue to strengthen cooperation with domestic and foreign universities, continue to improve the status of enterprises in the domestic pharmaceutical intermediate industry and the level of scientific and technological innovation, and enhance the market competitiveness of enterprises.